21d • General discussion
GLPs and the Menopause
Menopausal weight gain is not simply about willpower or calories. Learn how GLP-1 medicines may help some women — and why muscle, protein, HRT, testosterone and insulin resistance still matter.
Why menopause changes the weight-loss conversation
Many women reach midlife and feel as if the rules have suddenly changed. The same diet that once worked no longer works. Weight appears around the middle, cravings become harder to control, sleep deteriorates, brain fog creeps in, energy drops. And, all too often, the advice they receive is painfully simplistic and (some would argue) verging on misogynist.
“Eat less and move more.” That advice is entirely wrong.
For our view on why Calorie Counting is the wrong approach click here:
Menopause is not just the end of periods. It is a major hormonal and metabolic transition. Falling oestrogen affects body fat distribution, insulin sensitivity, muscle mass, sleep, mood, vascular health, bone density, urogenital health and appetite regulation. That’s why GLP-1 medicines such as semaglutide and tirzepatide have attracted so much attention. They can reduce appetite, improve blood glucose control and help people lose significant amounts of weight.
But in menopausal women, the question is not simply: “Will this help me lose weight?” the right question is: “Can this help improve metabolic health without making muscle, nutrition, hormones or long-term resilience worse?”
That is absolutely the conversation we should be having.
Menopausal weight gain is metabolic, not moral
One of the most common experiences during perimenopause and menopause is weight gain around the abdomen. This is not just cosmetic because increased visceral fat is strongly associated with insulin resistance, fatty liver, raised blood pressure, inflammation and cardiovascular risk. The frustrating part is that most women have not really changed their behaviour. They may be eating similarly, drinking similarly and exercising similarly (even exercising more and eating less perhaps) but their biology has changed.
Several factors converge:
- falling oestrogen
- poorer sleep
- loss of lean muscle
- increased stress reactivity
- lower resting energy expenditure
- increased insulin resistance
- more hunger and cravings
- greater tendency to store fat centrally
This is why menopausal weight gain should not be dismissed as a failure of willpower. It is often a sign that the metabolic terrain has changed. This is where GLP-1 medicines (used intelligently) may be truly useful. Of course they do not “fix menopause”, but they can help address some of the downstream metabolic problems: appetite dysregulation, food noise, blood glucose variability, insulin resistance and central weight gain. That said they are not a substitute for a proper menopause and metabolic health plan. Women who need broader support may benefit from a more comprehensive approach such as the ProLongevity metabolic health programme, or, for those stopping injections and worried about rebound weight gain, ProLongevity Essentials.
For women who want specialist HRT advice from a medical doctor with special expertise you need look no further than our associate Dr Karen Benson
What GLP-1 medicines actually do
GLP-1 medicines mimic or amplify gut hormone signalling involved in appetite, satiety, insulin secretion and gastric emptying. Semaglutide acts mainly through the GLP-1 receptor. Tirzepatide acts on both GIP and GLP-1 pathways. You can read more about the mechanisms in our explainer: How GLP-1 drugs work for weight loss.
In practical terms, many people experience:
- Reduced hunger
- Reduced “food noise”
- Earlier fullness
- Fewer cravings
- Improved blood glucose control
- Easier weight loss
- Less inflammation
This can be transformative, especially for women who feel they have spent decades fighting their appetite. But these medicines are powerful. Nausea, constipation, diarrhoea, vomiting, reflux, dehydration and gallbladder problems can occur. Rarely, serious complications such as pancreatitis require urgent medical attention.
We have covered this wider risk-benefit picture in The Hidden Dangers of the Weight Loss Jab and in our Mounjaro review.
So the issue is not whether GLP-1s “work”. They do! The issue is whether they are being used wisely.
Why menopausal women may respond differently
The evidence specifically in menopausal women is still developing. That matters.
Most large GLP-1 weight-loss trials include women, but they were not designed primarily as menopause studies.There are, however, important signals.
A 2024 study in postmenopausal women with overweight or obesity treated with semaglutide found that women using hormone therapy appeared to have a better weight-loss response than those not using hormone therapy. This does not prove that HRT “boosts” semaglutide in every woman, but it supports the idea that hormonal context may affect metabolic response. There is also growing interest in whether menopausal status affects body composition, appetite response, lean mass preservation and long-term weight maintenance during GLP-1 treatment.
The honest interpretation is this:
GLP-1s can be highly effective in midlife women, but menopause-specific prescribing should be more thoughtful than simply escalating the dose until the scales move.
That is especially important because a woman may be prescribed GLP-1 medication by one provider, HRT by another, and receive lifestyle advice from somewhere else entirely. In our view, those conversations should be joined up. That’s precisely how we work with our in-house GP.
HRT, testosterone and GLP-1s: get the hormonal foundation right
As we’ve already sad, GLP-1 medicines can help with appetite, cravings, glucose control and weight loss, but they are not menopause treatment. They do not replace oestrogen, progesterone or testosterone where these are clinically indicated. This distinction matters because menopause is a hormonal transition that affects sleep, mood, visceral fat, insulin sensitivity, bone density, urogenital health, muscle and cardiovascular risk. If a woman presents with midlife weight gain, fatigue, brain fog, poor sleep and low mood, she may not simply need an appetite suppressant. She may need a proper menopause review.
For patients needing specialist HRT input, we work closely with Dr Karen Benson, our in-house GP and HRT specialist. Dr Benson also works from Letchworth Pharmacy’s private GP clinic, where patients can access personalised GP-led support. You can also read more about our Private Menopause Clinic in Letchworth.
In general, transdermal oestrogen (patches, gel or spray) is often preferred over oral oestrogen, particularly in women with metabolic or vascular risk factors. Oral oestrogen passes first through the liver, which can influence clotting factors, triglycerides, inflammatory markers and binding proteins. Transdermal oestrogen largely avoids this first-pass hepatic metabolism. This is especially relevant in women with central weight gain, raised triglycerides, insulin resistance, fatty liver risk, hypertension, migraine, obesity or other cardiovascular risk factors. Oral HRT is not necessarily contra-indicated but the route of administration should be chosen deliberately.
It is also relevant for women using GLP-1 medicines, because semaglutide and tirzepatide delay gastric emptying. The full impact on oral HRT absorption is not yet clear, but the British Menopause Society has highlighted this as an area where data are lacking. In practical terms, women using oral HRT, oral progesterone or oral contraception should make sure their prescriber knows they are using a GLP-1.
Progesterone still matters. For women with a uterus, oestrogen should generally not be used without appropriate endometrial protection. If a woman is experiencing nausea, vomiting, erratic medicine timing, unscheduled bleeding or gastrointestinal side effects while taking a GLP-1, her HRT regimen should be reviewed rather than ignored.
Testosterone should always be part of the conversation: women produce testosterone, and levels tend to decline with age. Testosterone is not a weight-loss drug, and it should not be prescribed casually. But in properly selected women, it may be relevant to low sexual desire, reduced arousal, fatigue, motivation, wellbeing and quality of life. This matters because a woman may present with “low energy”, “brain fog”, “loss of drive” or “not feeling like herself” and be offered only weight-loss treatment or indeed HRT but without considering testosterone. The problem may be partly hormonal and partly lifestlye so its critical to consider all relevant factors.
At ProLongevity, our view is simple: GLP-1s can be a valuable metabolic tool, but they should sit within a broader menopause-aware plan. That means reviewing HRT, considering testosterone where appropriate, prioritising protein and resistance training, and measuring health improvements beyond the number on the scales.
The biggest mistake: losing muscle while losing weight
For menopausal women, weight loss alone is not the goal. The real goal is to lose visceral fat while preserving (or ideally building) lean muscle. This is crucial because muscle is not just “tone”. It is a metabolic organ. It helps regulate glucose disposal, insulin sensitivity, strength, balance, independence and healthy ageing.
During and after menopause, women are already at greater risk of:
- Sarcopenia
- Reduced bone density
- Frailty
- Falls
- Reduced metabolic flexibility
- Poorer glucose handling
A GLP-1 medicine that suppresses appetite too aggressively can unintentionally reduce protein intake. If a woman eats less but does not prioritise protein and resistance training, weight loss may include a clinically meaningful amount of lean mass. That is not a win.
A better GLP-1 plan for menopausal women should include:
- Protein at each meal
- Resistance training two to four times per week
- Adequate electrolytes and hydration
- Sufficient dietary fat
- Fibre from low-glycaemic whole foods
- Monitoring of strength, waist circumference and metabolic markers — not just scale weight
This is central to our approach at ProLongevity, where the aim is not simply weight loss, but better metabolic health and long-term resilience.
The scale is a crude instrument: Waist, strength, HbA1c, fasting insulin, triglycerides, HDL, blood pressure, sleep and how someone feels often tell a better story.
Cravings, appetite and “food noise”
Many menopausal women describe a change in appetite that feels almost alien. They may find themselves hungrier, more snack-driven or more vulnerable to carbohydrate cravings, particularly when sleep is poor. This is not simply lack of discipline! Sleep disruption, stress hormones, insulin resistance and changes in sex hormones can all alter hunger signalling. GLP-1 medicines can be useful here because they act partly through appetite regulation and satiety pathways. For some women, the most powerful effect is not dramatic weight loss. It is the quietening of the internal battle with food.
That said, appetite suppression is a double-edged sword. If it helps someone stop ultra-processed snacking and regain control, that is useful, but if it leads to under-eating, nausea, inadequate protein and muscle loss, it becomes counterproductive. The goal must never be: “Eat as little as possible.” The ultimate goal must be: “Eat enough of the right foods, with less compulsion and better metabolic control.” This is also why stopping injections without a plan can be such a problem. ProLongevity Essentials was designed specifically to help people understand why rebound happens and how to rebuild sustainable metabolic control: Stopping GLP-1 injections without the weight gain.
Contraception, fertility and pregnancy: do not ignore this
Perimenopausal does not mean infertile! This is particularly important because GLP-1 treatment and weight loss may improve ovulation in some women, especially those with insulin resistance or PCOS. At the same time, tirzepatide can reduce the reliability of oral contraception. Women taking GLP-1 medicines should not use them during pregnancy, while trying to conceive or while breastfeeding. Current UK safety advice is that semaglutide should be stopped at least two months before trying to conceive, and tirzepatide should be stopped at least one month before trying to conceive. Women taking tirzepatide should also be careful not to rely on oral contraception alone when starting treatment or increasing the dose. A non-oral method or additional barrier contraception may be needed.
This is not a minor detail. Any woman of child-bearing potential using GLP-1 treatment needs a clear contraception plan.
So, are GLP-1s a good option for menopausal weight gain?
Sometimes, yes. But they should be used as part of a metabolic strategy, not as a cosmetic shortcut.
A good candidate might be a woman with:
- Central weight gain
- Raised waist circumference
- Insulin resistance or prediabetes
- Fatty liver risk
- Hypertension or dyslipidaemia
- Persistent cravings or food noise
- Previous failed calorie-restriction attempts
- Obesity-related joint pain
- Sleep apnoea risk
- Strong family history of type 2 diabetes or cardiovascular disease
A poor plan would be:
- Escalating the dose rapidly
- Tolerating nausea as proof it is “working”
- Ignoring protein intake
- Doing no resistance training
- Failing to review HRT and contraception
- Ignoring testosterone where symptoms suggest it may be relevant
- Measuring success only by scale weight
- Stopping abruptly without a maintenance plan
The dose should be the lowest effective dose, not automatically the highest tolerated dose. The objective is long-term metabolic improvement, not short-term appetite obliteration.
For patients in Hertfordshire, Letchworth Pharmacy’s weight management service provides a local route into pharmacy-supported weight management. For patients in Kent, Pierremont Pharmacy’s weight management service explains our broader pharmacy-led approach.
The clinical hierarchy: hormones, metabolism, muscle — then appetite
A sensible approach is to look at the whole picture:
First, clarify menopause status and symptoms. Are there hot flushes, night sweats, sleep disturbance, mood changes, brain fog, vaginal or urinary symptoms, libido changes, cycle changes or bleeding concerns?
Second, review HRT properly. What oestrogen is being used? Is it oral or transdermal? Is progesterone needed? Is endometrial protection adequate? Is testosterone relevant? Are there contraindications or risk factors?
Third, assess metabolic health. Waist circumference, blood pressure, HbA1c, fasting insulin where useful, lipids, triglycerides, HDL, liver markers, fatty liver risk, sleep apnoea risk and family history all matter.
Fourth, decide whether GLP-1 therapy adds value. It may be highly appropriate where there is central obesity, insulin resistance, prediabetes, food noise, hypertension, fatty liver risk or repeated weight regain.
Fifth, protect muscle and bone from day one. That means protein, resistance training, vitamin D where appropriate, strength tracking and avoiding excessive appetite suppression.
The mistake is to frame GLP-1s as a replacement for menopause medicine. They are not. They are a metabolic tool that may work extremely well alongside good HRT care, nutrition and resistance training.
For women who want a deeper, personalised metabolic approach, the main ProLongevity programme is designed to look beyond weight and focus on the underlying drivers of metabolic dysfunction.
The ProLongevity view
For menopausal women, GLP-1s can be a genuinely useful tool. But they are only one tool and the foundations still matter:
- HRT review where appropriate
- Testosterone assessment where symptoms suggest it may be relevant
- Protein to preserve muscle
- Resistance training to maintain strength and insulin sensitivity
- Sleep to regulate appetite and stress hormones
- Low-glycaemic nutrition to reduce glucose and insulin excursions
- Metabolic markers to track actual health improvement
- A long-term exit or maintenance strategy
Menopause is not a failure of willpower. Far from it. Its a biological transition that deserves better than simplistic diet advice. GLP-1s may help many women regain control of appetite and weight. But the real prize is not simply being smaller. The real prize is becoming metabolically healthier, stronger, sharper and more resilient for the decades ahead.
Local support and next steps
If you are concerned about menopausal weight gain, cravings, insulin resistance or GLP-1 medication, the best next step is a proper assessment rather than guesswork.
For personalised metabolic health support, visit ProLongevity.
For help coming off GLP-1 injections or avoiding rebound weight gain, visit ProLongevity Essentials.
For menopause, HRT, testosterone and GP-led review, visit Dr Karen Benson or read more about the Private Menopause Clinic at Letchworth Pharmacy.
For local pharmacy-led weight management in Hertfordshire, visit Letchworth Pharmacy.
For local pharmacy-led weight management in Broadstairs and Kent, visit Pierremont Pharmacy.
And Finally:
Concerned about menopausal weight gain, cravings or insulin resistance?
At ProLongevity, we look beyond the number on the scales. We help you understand your metabolism, preserve muscle, improve blood glucose control and use GLP-1 medicines safely where appropriate. For patients who need specialist menopause input, we can also work alongside Dr Karen Benson, our in-house GP and HRT specialist, to ensure HRT, testosterone and wider menopause care are properly considered.
0
1 comment
GLPs and the Menopause
powered by
skool.com/prolongevity-essentials-8320
ProLongevity Essentials | Free | Pharmacist-Led Community
Suggested communities
Powered by